NKGen Biotech, Inc. Warrants
NKGNW
NKGNW was delisted on the 4th of March, 2025.
23 hedge funds and large institutions have $2.93M invested in NKGen Biotech, Inc. Warrants in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$227K |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$163K |
| 3 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$150K |
| 4 |
6CM
683 Capital Management
New York
|
+$125K |
| 5 |
FTCM
Fir Tree Capital Management
New York
|
+$125K |
Top Sellers
NKGNW Hedge Fund Activity: Q3 2021 in Review
23 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Warrants (NKGNW) for Q3 2021, worth a combined $2.93M.
Buyers outnumbered sellers: 23 funds opened new NKGNW positions and 0 closed out — a net gain of 23 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $227K.
- 23 institutional investors held NKGen Biotech, Inc. Warrants (NKGNW) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $2.93M of NKGen Biotech, Inc. Warrants stock for Q3 2021.
- 23 funds opened new NKGen Biotech, Inc. Warrants positions in Q3 2021 and 0 closed out, a net change of +23 holders.
- The largest NKGen Biotech, Inc. Warrants buyer in Q3 2021 was Adage Capital Partners, an estimated $227K added.
Based on aggregated 13F filings for Q3 2021.